For the Inventor, By the Inventor

Enter inventor name

San Francisco, CA, United States of America

R Jeffrey Neitz

USPTO Granted Patents = 19 (Patent Applications = 15)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 11.9

ph-index = 4

Forward Citations = 50(Granted Patents)

Location History:

San Francisco, CA (US) (2003 - 2017)
Cambridge, MA (US) (2018)

Company Filing History:

Elan Pharmaceuticals, Inc.

Imago Pharmaceuticals, Inc.

Athena Neurosciences, Inc.

4. 2 out of 4,442

Eli Lilly and Company

5. 8 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2018

Loading Chart...

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9884828 - Substituted cinnolines as inhibitors of LRRK2 kinase activity (2018-02-06),

2. 9796706 - Inhibitors of Jun N-terminal kinase (2017-10-24),

3. 9073891 - Inhibitors of Jun N-terminal kinase (2015-07-07),

4. 8541418 - Inhibitors of polo-like kinase (2013-09-24),

5. 8450363 - Inhibitors of Jun N-terminal kinase (2013-05-28),

6. 8445503 - Inhibitors of polo-like kinase (2013-05-21),

7. 7906556 - Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors (2011-03-15),

8. 7432379 - [object Object] (2008-10-07),

9. 7417152 - [object Object] (2008-08-26),

10. 7153847 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2006-12-26),

11. 6951854 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2005-10-04),

12. 6683075 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use (2004-01-27),

13. 6667305 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-12-23),

14. 6653303 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-11-25),

15. 6635632 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-10-21),

Title: R Jeffrey Neitz: A Pioneer in Pharmaceutical Innovations

Introduction

R Jeffrey Neitz is a notable inventor based in San Francisco, California, recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 19 patents, Neitz has focused his research on developing innovative compounds aimed at treating complex disorders.

Latest Patents

Among Neitz's latest inventions are compounds characterized as substituted cinnolines, designed as inhibitors of LRRK2 kinase activity. This invention holds promise for the treatment and prevention of disorders such as Parkinson's disease. The patent details a structure according to Formula I, providing pharmaceutical compositions that include these compounds and methods for their utilization.

Another significant contribution is the patent for inhibitors of Jun N-terminal kinases (JNK), with a structure defined for effective treatment of disorders such as Alzheimer's disease. This includes not only the development of the compounds but also their pharmaceutical applications, enhancing the therapeutic landscape for these critical conditions.

Career Highlights

Throughout his career, R Jeffrey Neitz has worked with prestigious organizations, including Elan Pharmaceuticals, Inc. His expertise in pharmaceutical research has been instrumental in advancing innovative treatments across various medical fields.

Collaborations

Neitz has collaborated with esteemed professionals in the industry, including Jay S Tung and Jing Wu. These partnerships have enhanced the development of groundbreaking compounds and boosted the overall impact of his work in the pharmaceutical domain.

Conclusion

R Jeffrey Neitz continues to be a pioneering figure in pharmaceutical innovations, with a clear commitment to addressing significant health challenges. His latest patents reflect a dedication to improving treatment options for disorders like Parkinson's and Alzheimer's disease, underscoring the essential role of inventors in advancing healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…